Company Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Company Information
- CEO
- Lars Fruergaard Jorgensen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 77406
Contact Information
- Website
- https://www.novonordisk.com
- Address
- Novo Alle 1
- Country
- DK
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 238.84B market capitalization
- Trading Volume: 31.68M shares traded today
- Price Range: 52-week range of $45.05 - $139.74
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Novo Nordisk A/S
Novo Nordisk A/S (NVO) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 238.84B, the company represents a significant player in its market. The stock is currently trading at $53.75 with a positivedaily change of 2.56%.
The company's 77406 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 13.71, beta of 0.27, and 52-week price range from $45.05 to $139.74when evaluating investment opportunities.
Why Invest in Novo Nordisk A/S?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Lars Fruergaard Jorgensen
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.